{"filing":{"accession_number":"0001493152-26-027290","cik":"0000073290","ticker":"BMRA","company_name":"BIOMERICA INC","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/73290/000149315226027290/form8-k.htm"},"events":[{"id":6930,"run_id":6076,"accession_number":"0001493152-26-027290","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Biomerica entered into a Securities Purchase Agreement on May 29, 2026 to sell 78,750 shares (approximately 6%) of Diagnosis S.A. for $500,000 to buyers affiliated with CEO Zackary Irani. This constitutes a material disposition of a significant equity stake in an investee company. The transaction is disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation), indicating the company views it as material. The sale involves a secured promissory note with interest and specific maturity terms, making it a structured financial transaction with material implications for the company's asset portfolio.","company_name":"BIOMERICA INC","ticker":"BMRA","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":4482,"accession_number":"0001493152-26-027290","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Biomerica entered into a Securities Purchase Agreement on May 29, 2026 to sell 78,750 shares (approximately 6%) of Diagnosis S.A. for $500,000 to buyers affiliated with CEO Zackary Irani. This constitutes a material disposition of a significant equity stake in an investee company. The transaction is disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation), indicating the company views it as material. The sale involves a secured promissory note with interest and specific maturity terms, making it a structured financial transaction with material implications for the company's asset portfolio.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:22:26.806951+00:00","company_name":"BIOMERICA INC","ticker":"BMRA","filing_date":"2026-06-04"}]}